Fluphenazine — $0 on Listed Strengths
Fluphenazine is $0 on listed strengths only. Other strengths are not a blanket $0.
Fluphenazine Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | $0 on listed strengths |
| Typical Retail | $162.00 |
$0 on listed strengths: 10mg Tablet (max 90); 1mg Tablet (max 90); 2.5mg Tablet (max 90); 5mg Tablet (max 90)
About Fluphenazine
Fluphenazine is a prescription medication. Ask your doctor if Fluphenazine is right for you.
How to Check Fluphenazine Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Fluphenazine at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Mental Health
About Fluphenazine
Fluphenazine is a vital medication used to manage severe mental health conditions. Understanding its role and how to access it affordably is crucial. At TheDrugClub, we're dedicated to making essential prescriptions like fluphenazine accessible and budget-friendly, ensuring you can focus on your health without the added financial stress.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Fluphenazine is approved for (FDA label)
Fluphenazine hydrochloride tablets are indicated in the management of manifestations of psychotic disorders. Fluphenazine hydrochloride has not been shown effective in the management of behavioral complications in patients with mental retardation.
Source: Read the full FDA label on DailyMed. Label effective date: July 3, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Boxed warning for Fluphenazine (FDA label)
WARNING Incr eased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Fluphenazine hydrochloride is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS ).
Source: FDA prescribing information (DailyMed). Set ID: 91b85b8d-4c10-4395-915e-272b81ef3b12. SPL document ID: 55b89c3d-bcb4-01ee-e063-6394a90a7f03. Label effective date: July 3, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Fluphenazine (FDA label)
Central Nervous System: The side effects most frequently reported with phenothiazine compounds are extrapyramidal symptoms including pseudoparkinsonism, dystonia, dyskinesia, akathisia, oculogyric crises, opisthotonos, and hyperreflexia. Most often these extrapyramidal symptoms are reversible; however, they may be persistent (see below ). With any given phenothiazine derivative, the incidence and severity of such reactions depend more on individual patient sensitivity than on other factors, but dosage level and patient age are also determinants. Extrapyramidal reactions may be alarming, and the patient should be forewarned and reassured. These reactions can usually be controlled by administration of antiparkinsonian drugs such as benztropine mesylate or intravenous caffeine and sodium benzoate injection, and by subsequent reduction in dosage.
Source: FDA prescribing information (DailyMed). Set ID: 91b85b8d-4c10-4395-915e-272b81ef3b12. SPL document ID: 55b89c3d-bcb4-01ee-e063-6394a90a7f03. Label effective date: July 3, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Fluphenazine (FDA label)
Phenothiazines are contraindicated in patients with suspected or established subcortical brain damage, in patients receiving large doses of hypnotics, and in comatose or severely depressed states. The presence of blood dyscrasia or liver damage precludes the use of fluphenazine hydrochloride. Fluphenazine hydrochloride is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross-sensitivity to phenothiazine derivatives may occur.
Source: FDA prescribing information (DailyMed). Set ID: 91b85b8d-4c10-4395-915e-272b81ef3b12. SPL document ID: 55b89c3d-bcb4-01ee-e063-6394a90a7f03. Label effective date: July 3, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.